Portable, 3D-Printed Bioreactor Enabling Rapid, Automated, Closed, and Scalable Cell and Gene Therapy Manufacturing

ALS gene therapy KLTO‑202 advances to manufacturing phase

Klotho Neurosciences is advancing KLTO‑202, its gene therapy candidate for amyotrophic lateral sclerosis (ALS), to the manufacturing and process development phase — with an eye toward trials in humans beginning next year. The manufacturing phase is expected to last about eight months, and will be followed by 4-6 months of regulatory preparation, including meetings with the U.S. Food and Drug Administration (FDA), Klotho stated in a company press…

Portable, 3D-Printed Bioreactor Enabling Rapid, Automated, Closed, and Scalable Cell and Gene Therapy Manufacturing

Portable, 3D-Printed Bioreactor Enabling Rapid, Automated, Closed, and Scalable Cell and Gene Therapy Manufacturing Christy Toms Mon, 07/07/2025

Klotho Neurosciences advances production of gene therapy for ALS

Klotho Neurosciences advances ALS treatment with KLTO-202 gene therapy entering manufacturing phase for clinical trials. The RNA-based therapy targets the neuroprotective alpha-Klotho protein, showing promise for ALS, Alzheimer's, and Parkinson's patients. Clinical trials expected by Q3 2026.